Intra-prostatic UroLift® implants for benign prostatic hyperplasia: Preliminary results of the four first cases performed in France;Pose d'implants UroLift® intra-prostatiques pour hyperplasie bénigne de la prostate : Résultats préliminaires des quatre premiers cas réalisés en France

Progres en Urologie

Volumn 22, Issue 10, 2012, Pages 590-597

  Delongchamps, N B ^a   Conquy, S ^a   Defontaines, J ^a   Zerbib, M ^a   Peyromaure, M ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Benign prostate hyperplasia; Mini invasive; UroLift

Indexed keywords

AGED; ARTICLE; CASE REPORT; FEASIBILITY STUDY; FRANCE; HUMAN; MALE; MIDDLE AGED; PROSTATE HYPERTROPHY; PROSTHESES AND ORTHOSES;

AGED; FEASIBILITY STUDIES; FRANCE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTHESES AND IMPLANTS;

EID: 84865537695     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2012.05.001     Document Type: Article

References (15)

1. Costa P., Ben Naoum K., Boukaram M., Wagner L., Louis J.F. Benign prostatic hyperplasia (BPH): prevalence in general practice and practical approach of French general practitioners. Results of a study based on 17,953 patients. Prog Urol 2004, 14:33-39.
2. Rhodes P.R., Krogh R.H., Bruskewitz R.C. Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology 1999, 53:1090-1098.
3. http://www.sante.gouv.fr/IMG/pdf/OBSERVAtoire_des_Pratiques_en_Urologie_Observapur.
4. Debruyne F., Koch G., Boyle P., et al. Comparison of a phytotherapeutic agent (permixon) with an α-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomised international study. Eur Urol 2002, 41:497-507.
5. Djavan B., Marberger M. A meta-analysis on the efficacy and tolerability of 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999, 36:1-13.
6. Lourenco T., Armstrong N., N'Dow J., Nabi G., Deverill M., Pickard R., et al. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess 2008, 12:1-146.
7. Gravas S., Laguna P., Kiemeney L.A., de la Rosette J.J. Durability of 30minutes high-energy transurethral microwave therapy for the treatment of BPH: a study of 213 patients with and without urinary retention. Urology 2007, 69:854-858.
8. Schatzl G., Madersbacher S., Lang T., Marberger M. The early postoperative morbidity of transurethral resection of the prostate and of four minimally invasive treatment alternatives. J Urol 1997, 158:105-110.
9. Bruskewitz R., Issa M.M., Roehrborn C.G., et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998, 159:1583-1588.
10. Barry Delongchamps N., Robert G., Descazeaud A., Cornu J.N., Azzouzi A.R., Haillot O., et al. Traitement chirurgical de l'hyperplasie bénigne de la prostate par thermothérapie et autres techniques émergentes : revue de littérature du CTMH de l'AFU. Prog Urol 2012, 22:87-92.
11. Woo H.H., Chin P.T., McNicholas T.A., Gill H.S., Plante M.K., Bruskewitz R.C., et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 2011, 108:82-88.
12. Chin P.T., Bolton D.M., Jack G., Rashid P., Thavaseelan J., Yu R.J., et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012, 79:5-11.
13. Woo H.H., Bolton D.M., Laborde E., Jack G., Chin P.T., Rashid P., et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 2012, 9:568-575.
14. Hellstrom W.J., Sikka S.C. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006, 176:1529-1533.
15. http://www.clinicaltrials.gov/ct2/show/NCT01294150%3Fterm=UroLift%26rank=1.